Management Comment "We remain on track to complete patient enrollment later this year in our landmark global phase 3 CONVERT study," said Will Lewis, president and chief executive officer ofInsmed. "ARIKAYCE has the potential to make a significant difference to patients whose NTM lung disease persists despite long-term courses of multi-drug regimens. We are committed to achieving our ultimate goal of making ARIKAYCE available to patients in the US, Europe, and Asia who are living with the devastating effects of this disease."